Multiple sclerosis treatment requires not only DMTs to slow disease progression but also active management of the symptoms that produce most of patients’ day-to-day disability — fatigue, spasticity, bladder dysfunction, walking impairment, cognitive issues, mood, pain, and tremor. Effective symptomatic management can dramatically improve quality of life independent of DMT choice. This page covers the major MS symptom categories and the pharmacologic approaches to each.

Fatigue

  • One of the most common and disabling MS symptoms.
  • Amantadine: 100 mg AM and noon; first-line for many.
  • Modafinil: 100-400 mg AM; alternative; less commonly used due to schedule IV.
  • Armodafinil: 150-250 mg AM.
  • Methylphenidate: alternative; consider in selected patients.
  • SSRIs/SNRIs: if mood-related fatigue.
  • Non-pharm: heat avoidance, exercise programs, sleep optimization, cognitive behavioral therapy.

Spasticity

  • Baclofen: GABA-B agonist; oral 10-80 mg/day in divided doses.
  • Tizanidine: α2 agonist; 2-32 mg/day in divided doses.
  • Dantrolene: peripheral muscle effects; rarely used (hepatotoxicity).
  • Cyclobenzaprine: less effective for MS spasticity.
  • Botulinum toxin: focal spasticity (e.g., lower limb extensor, plantar flexors).
  • Intrathecal baclofen pump: severe spasticity refractory to oral; programmable.
  • Withdrawal of intrathecal baclofen: life-threatening (high fever, rebound spasticity, hallucinations, seizures); emergency.
  • Cannabis-based therapy: nabiximols (Sativex) approved in some markets.

Bladder Dysfunction

Overactive Bladder / Urge Incontinence

  • Anticholinergics: oxybutynin, tolterodine, solifenacin, darifenacin.
  • Mirabegron (β3 agonist): alternative, less anticholinergic burden.
  • Botulinum toxin to detrusor: for refractory.
  • Sacral nerve stimulation: surgical option.

Retention / Incomplete Emptying

  • α1-blockers (tamsulosin) — limited use in women but selected men.
  • Intermittent self-catheterization: mainstay.
  • Urology consultation often needed.

Mixed / Dyssynergia

  • Often requires combined approach.
  • Urology evaluation important.

Walking Impairment

  • Dalfampridine (4-aminopyridine, Ampyra): K⁺ channel blocker; improves nerve conduction in demyelinated axons; improves walking speed.
  • 10 mg BID; do not exceed (seizure risk).
  • Avoid in patients with seizure history or moderate-severe renal impairment.
  • Compounded 4-AP also used.
  • Subset of patients (~35%) respond; trial 2-8 weeks.

Cognitive Dysfunction

  • No FDA-approved treatments for MS cognitive dysfunction.
  • Donepezil, memantine: tested but not shown effective for MS.
  • Modafinil/amantadine: may help fatigue-related cognitive symptoms.
  • Cognitive rehabilitation: evidence for benefit.
  • Address underlying contributors: sleep, depression, medication side effects, comorbid conditions.

Depression

  • Common (~30-50% of MS patients).
  • SSRIs: first-line (sertraline, escitalopram).
  • SNRIs: alternative.
  • Avoid TCAs in elderly (anticholinergic).
  • Watch for interaction with DMTs (rare).
  • Psychotherapy + medication often combination.

Pseudobulbar Affect (PBA)

  • Sudden episodes of laughing or crying disconnected from mood.
  • Dextromethorphan/quinidine (Nuedexta): FDA-approved for PBA in MS, ALS, stroke, dementia.
  • Mechanism: NMDA antagonism + SERT/NET; quinidine boosts dextromethorphan levels by CYP2D6 inhibition.
  • Side effects: dizziness, falls, GI; QT prolongation (cardiac monitoring in selected).

Sleep Disturbance

  • Insomnia common in MS.
  • Pharmacologic: melatonin, doxepin (low-dose), trazodone, eszopiclone (limited use), benzodiazepines (avoid chronically).
  • Address underlying: spasticity, nocturia, anxiety, depression.
  • Sleep apnea: increasingly recognized; screen.

Restless Legs Syndrome / Periodic Limb Movements

  • Increased prevalence in MS.
  • α2δ ligands (gabapentin, pregabalin): first-line.
  • Iron supplementation if ferritin <75-100.
  • Dopamine agonists: secondary line (augmentation risk).

Pain Syndromes

Neuropathic Pain

  • Gabapentin, pregabalin: first-line.
  • SNRIs (duloxetine, venlafaxine): effective.
  • TCAs (amitriptyline, nortriptyline): effective; lower doses for pain than depression.
  • Carbamazepine: trigeminal neuralgia (common in MS).
  • Topical lidocaine: localized.

Trigeminal Neuralgia in MS

  • Common manifestation; sometimes presenting feature.
  • Carbamazepine, oxcarbazepine: first-line.
  • Surgical options: microvascular decompression, gamma knife, percutaneous balloon compression.

Lhermitte’s Sign / Electric Shock Sensations

  • Gabapentin, pregabalin: first-line.
  • Carbamazepine: alternative.

Tremor / Ataxia

  • Tremor: clonazepam, propranolol, primidone, gabapentin; deep brain stimulation for refractory.
  • Ataxia: pharm options limited; physical therapy mainstay.

Sexual Dysfunction

  • Both men and women affected.
  • PDE5 inhibitors (sildenafil, tadalafil): men.
  • Topical lubricants, water-based: women.
  • Address relationship aspects; PT for pelvic floor.

Vertigo / Dizziness

  • Acute MS attack: methylprednisolone for relapse.
  • Symptom relief: meclizine, ondansetron.
  • Vestibular rehabilitation: PT.

Optic Neuritis

  • Acute: methylprednisolone 1 g IV daily × 3-5 days; oral steroid taper not needed.
  • Optic Neuritis Treatment Trial: showed IV steroid speeds recovery but does not change long-term visual outcome.
  • Plasmapheresis: severe steroid-refractory.

Acute MS Relapse Management

  • Methylprednisolone 1000 mg IV daily × 3-5 days OR equivalent oral prednisone.
  • Plasmapheresis for severe steroid-refractory.
  • IVIG occasionally.
  • Acute steroid does not modify disease trajectory; DMT does.

🔍 Did You Know?

The mechanism of dalfampridine (4-aminopyridine) in improving walking in MS provides a beautiful example of how understanding pathophysiology can lead to elegantly targeted therapy. Demyelinated axons leak K⁺ from exposed segments and conduct nerve impulses poorly because of K⁺ channel dysfunction. Dalfampridine — a potassium channel blocker — selectively blocks these K⁺ channels, improving nerve conduction through demyelinated segments. In clinical trials, approximately 35% of MS patients show a clinically significant improvement in walking speed and endurance, with effects often noticeable within 2-4 weeks. The lesson generalizes: treating the symptom of demyelinated nerve dysfunction directly (rather than just slowing disease) is a complementary therapeutic approach. This principle has prompted research into other ion-channel modulators for neurological symptoms in MS and other demyelinating conditions. For practicing neurologists, the key clinical pearls: (1) trial dalfampridine for 2-8 weeks; (2) responders should have measurable walking speed improvement on Timed 25-Foot Walk; (3) seizure threshold is a concern — avoid in patients with seizure history or significant renal impairment (drug is renally cleared); (4) do not exceed 10 mg BID due to dose-related toxicity. The drug exemplifies the philosophy that symptomatic and disease-modifying therapies are complementary, not competing, in modern MS care.

Pitfalls and Pearls

  • Fatigue: amantadine first-line; modafinil/armodafinil alternatives.
  • Spasticity: baclofen (GABA-B); tizanidine (α2); intrathecal baclofen pump for refractory.
  • Bladder OAB: mirabegron may have less cognitive burden than anticholinergics.
  • Botulinum toxin: focal spasticity and detrusor overactivity.
  • Dalfampridine (Ampyra): K⁺ channel blocker; walking improvement; 10 mg BID max.
  • Dextromethorphan/quinidine (Nuedexta): pseudobulbar affect.
  • Depression in MS: SSRIs first-line; CBT effective.
  • Trigeminal neuralgia in MS: carbamazepine; surgical options.
  • Neuropathic pain: gabapentin, pregabalin, SNRIs.
  • Acute relapse: methylprednisolone 1 g IV × 3-5 days.
  • Optic neuritis: IV methylprednisolone; speeds recovery.
  • Cognitive dysfunction: no FDA-approved drug; address contributors.
  • Tremor: clonazepam, propranolol; DBS for refractory.
  • Intrathecal baclofen withdrawal: life-threatening emergency.
  • Address underlying contributors: sleep, mood, comorbidities, medications.

References

  1. National Multiple Sclerosis Society. Symptom management resources.
  2. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732-738.
  3. Pittock SJ, Mayr WT, McClelland RL, et al. Quality of life is favorable for most patients with multiple sclerosis. Mult Scler J. 2004;10(6):667-672.
  4. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-1666.
  5. Drug treatments for spasticity due to multiple sclerosis (NICE guideline review). BMJ. 2014;349:g5876.
  6. Brashear A, Lambert M, Cleeland CS. Treatment of multiple sclerosis-related spasticity. Continuum (Minneap Minn). 2014;20(3):797-812.